Aadi Bioscience (AADI) Stock Price, News & Analysis

Company Overview

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Key Stats

• Today's Range: $1.97 to $2.08
• 50-Day Range: $1.45 to $2.04
• 52-Week Range: $1.21 to $3.81
• Volume: 107,824 shs
• Average Volume: 265,147 shs
• Market Capitalization: $49.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.67
• Consensus Rating: Hold

Aadi Bioscience Stock Analysis - MarketRank™

Aadi Bioscience scored higher than 13% of companies evaluated by MarketBeat, and ranked 892nd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Aadi Bioscience has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Aadi Bioscience has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aadi Bioscience are expected to grow in the coming year, from ($2.04) to ($0.94) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aadi Bioscience is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aadi Bioscience is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aadi Bioscience has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for AADI.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aadi Bioscience does not currently pay a dividend.

Dividend Growth

Aadi Bioscience does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for AADI.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

3 people have searched for AADI on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Aadi Bioscience to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aadi Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

37.30% of the stock of Aadi Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

52.08% of the stock of Aadi Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AADI Stock Analysis - Frequently Asked Questions

How have AADI shares performed this year?

Aadi Bioscience's stock was trading at $3.15 on January 1st, 2025. Since then, AADI stock has decreased by 36.2% and is now trading at $2.01.
View the best growth stocks for 2025 here.

How were Aadi Bioscience's earnings last quarter?

Aadi Bioscience, Inc. (NASDAQ:AADI) released its earnings results on Tuesday, March, 18th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.37. The company earned $7.24 million during the quarter, compared to the consensus estimate of $7.45 million. Aadi Bioscience had a negative net margin of 246.06% and a negative trailing twelve-month return on equity of 71.87%.
Read the conference call transcript.

When did Aadi Bioscience's stock split?

Aadi Bioscience shares reverse split on the morning of Friday, August 27th 2021. The 1-15 reverse split was announced on Thursday, August 26th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 25th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Aadi Bioscience's major shareholders?

Aadi Bioscience's top institutional investors include Simplex Trading LLC. Insiders that own company stock include Neil Desai, David James Lennon and Scott M Giacobello.
View institutional ownership trends.

How do I buy shares of Aadi Bioscience?

Shares of AADI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aadi Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aadi Bioscience investors own include Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Moderna (MRNA), NVIDIA (NVDA) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 3/18/2025
• Today: 6/18/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AADI
• CIK: 1422142
• Web: aadibio.com
• Phone: (424) 473-8055
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $1.67
• High Stock Price Target: $1.75
• Low Stock Price Target: $1.50
• Potential Upside/Downside: -17.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$65.76 million
• Net Margins: -246.06%
• Pretax Margin: -246.06%
• Return on Equity: -71.87%
• Return on Assets: -57.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.89
• Quick Ratio: 4.54

Sales & Book Value

• Annual Sales: $25.07 million
• Price / Sales: 1.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.29 per share
• Price / Book: 0.47

Miscellaneous

• Outstanding Shares: 24,697,000
• Free Float: 15,485,000
• Market Cap: $49.64 million
• Optionable: Optionable
• Beta: 0.68